KR20240067064A - 레티쿨로칼빈-3[rcn3] 변이체 및 인터류킨-4 수용체 알파[il4r] 길항제를 이용한 천식의 치료 - Google Patents
레티쿨로칼빈-3[rcn3] 변이체 및 인터류킨-4 수용체 알파[il4r] 길항제를 이용한 천식의 치료 Download PDFInfo
- Publication number
- KR20240067064A KR20240067064A KR1020247007006A KR20247007006A KR20240067064A KR 20240067064 A KR20240067064 A KR 20240067064A KR 1020247007006 A KR1020247007006 A KR 1020247007006A KR 20247007006 A KR20247007006 A KR 20247007006A KR 20240067064 A KR20240067064 A KR 20240067064A
- Authority
- KR
- South Korea
- Prior art keywords
- nucleic acid
- rcn3
- acid molecule
- subject
- complementary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pathology (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163250546P | 2021-09-30 | 2021-09-30 | |
| US63/250,546 | 2021-09-30 | ||
| PCT/US2022/077088 WO2023056254A1 (en) | 2021-09-30 | 2022-09-27 | Reticulocalbin-3 (rcn3) variants and treatment of asthma with interleukin-4 receptor alpha (il4r) antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240067064A true KR20240067064A (ko) | 2024-05-16 |
Family
ID=83902767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247007006A Pending KR20240067064A (ko) | 2021-09-30 | 2022-09-27 | 레티쿨로칼빈-3[rcn3] 변이체 및 인터류킨-4 수용체 알파[il4r] 길항제를 이용한 천식의 치료 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230151426A1 (https=) |
| EP (1) | EP4409037A1 (https=) |
| JP (1) | JP2024536001A (https=) |
| KR (1) | KR20240067064A (https=) |
| CN (1) | CN117957332A (https=) |
| CA (1) | CA3230302A1 (https=) |
| IL (1) | IL311480A (https=) |
| MX (1) | MX2024003921A (https=) |
| WO (1) | WO2023056254A1 (https=) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| WO2011156000A2 (en) * | 2010-06-07 | 2011-12-15 | Aerovance, Inc. | Use of il-4/il-13 antagonists to treat eosinophilic disorders |
| AR098155A1 (es) * | 2013-10-23 | 2016-05-04 | Genentech Inc | Métodos para diagnosticar y tratar trastornos eosinofílicos |
-
2022
- 2022-09-27 KR KR1020247007006A patent/KR20240067064A/ko active Pending
- 2022-09-27 US US17/935,785 patent/US20230151426A1/en active Pending
- 2022-09-27 JP JP2024513821A patent/JP2024536001A/ja active Pending
- 2022-09-27 EP EP22793348.8A patent/EP4409037A1/en active Pending
- 2022-09-27 CA CA3230302A patent/CA3230302A1/en active Pending
- 2022-09-27 IL IL311480A patent/IL311480A/en unknown
- 2022-09-27 MX MX2024003921A patent/MX2024003921A/es unknown
- 2022-09-27 CN CN202280059731.6A patent/CN117957332A/zh active Pending
- 2022-09-27 WO PCT/US2022/077088 patent/WO2023056254A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN117957332A (zh) | 2024-04-30 |
| EP4409037A1 (en) | 2024-08-07 |
| CA3230302A1 (en) | 2023-04-06 |
| JP2024536001A (ja) | 2024-10-04 |
| IL311480A (en) | 2024-05-01 |
| MX2024003921A (es) | 2024-04-22 |
| WO2023056254A1 (en) | 2023-04-06 |
| AU2022356375A1 (en) | 2024-03-14 |
| US20230151426A1 (en) | 2023-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116249787A (zh) | 用g蛋白偶联受体75(gpr75)抑制剂治疗肥胖症 | |
| JP2026004359A (ja) | Ｐｃｓｋ９調節物質及びｌｄｌｒ調節物質による敗血症の治療 | |
| US20240102013A1 (en) | Treatment Of Ophthalmic Conditions With Son of Sevenless 2 (SOS2) Inhibitors | |
| US20230287422A1 (en) | Triggering Receptor Expressed On Myeloid Cells 2 (TREM2) Variants And Uses Thereof | |
| US20230000897A1 (en) | Treatment Of Cerebrovascular Disease With Neurogenic Locus Notch Homolog Protein 3 (NOTCH3) Agents | |
| US20230151426A1 (en) | Reticulocalbin-3 (RCN3) Variants And Treatment Of Asthma With Interleukin-4 Receptor Alpha (IL4R) Antagonists | |
| AU2022356375B2 (en) | Reticulocalbin-3 (rcn3) variants and treatment of asthma with interleukin-4 receptor alpha (il4r) antagonists | |
| US20230192864A1 (en) | Treatment Of Lung Conditions With Integrin Subunit Alpha 1 (ITGA1) Inhibitors | |
| EP3986912A1 (en) | Treatment of decreased bone mineral density with zinc and ring finger 3 (znrf3) inhibitors | |
| EP4114975B1 (en) | Fascin-2 (fscn2) variant and use thereof | |
| CN113423435A (zh) | 使用花生四烯酸15-脂氧合酶(alox15)抑制剂治疗呼吸系统病症 | |
| US20210371930A1 (en) | Solute Carrier Family 26 Member 5 (SLC26A5) Variants And Uses Thereof | |
| US20230099109A1 (en) | Treatment Of Glaucoma With Rho Guanine Nucleotide Exchange Factor 12 (ARHGEF12) Inhibitors | |
| WO2023141577A2 (en) | Methods of improving health with apolipoprotein e (apoe) inhibitors | |
| US20230027007A1 (en) | Treatment of Hypertension With Solute Carrier Family 9 Isoform A3 Regulatory Factor 2 (SLC9A3R2) Inhibitors | |
| JP2024524554A (ja) | ピエゾ型機械受容イオンチャネル成分１（ｐｉｅｚｏ１）アゴニストによる静脈瘤の処置 | |
| CN118265529A (zh) | 使用camp应答元件结合蛋白3样3(creb3l3)抑制剂的肝病治疗 | |
| CA3141309A1 (en) | Synaptojanin 2 (synj2) variants and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |